Portage Biotech (NASDAQ:PRTG) Stock Price Down 7.2% – Time to Sell?

Posted by Scott Moore on Jan 12th, 2025

Shares of Portage Biotech Inc. (NASDAQ:PRTG – Get Free Report) traded down 7.2% during mid-day trading on Friday . The stock traded as low as $4.30 and last traded at $4.37. 27,346 shares traded hands during trading, a decline of 57% from the average session volume of 63,041 shares. The stock had previously closed at $4.71.

Portage Biotech Stock Down 7.2 %

The business has a fifty day moving average price of $4.72 and a 200-day moving average price of $4.71. The company has a market cap of $4.58 million, a P/E ratio of -0.10 and a beta of 1.33.

Institutional Investors Weigh In On Portage Biotech

A hedge fund recently bought a new stake in Portage Biotech stock. Virtu Financial LLC acquired a new position in Portage Biotech Inc. (NASDAQ:PRTG – Free Report) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 10,919 shares of the company’s stock, valued at approximately $73,000. Virtu Financial LLC owned approximately 1.04% of Portage Biotech as of its most recent SEC filing. 13.36% of the stock is currently owned by hedge funds and other institutional investors.

Portage Biotech Company Profile

(Get Free Report)

Portage Biotech Inc, a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline includes PORT-2 for treatment of refractory NSCLC, melanoma, and refractory melanoma that is in phase I and phase II clinical trials; PORT-3, for treatment of solid tumors, which is in phase I clinical trials; PORT-6, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ia clinical trials; PORT-7, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ib clinical trials; PORT-1, an intratumoral amphiphilic solutions for treatment of advanced soft tissue sarcoma, which is in phase 3 clinical trials; PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors that is in preclinical trials.